Wednesday, Dec 9, 1992
South San Francisco, Calif. -- December 9, 1992 --Genentech, Inc. (NYSE: GNE) announced today that it has been issued U.S. patent No. 5,169,762 relating to human nerve growth factor (NGF) made by recombinant DNA technology. The patent covers nucleic acids, vectors, and host cells used for making recombinant NGF.
A counterpart European patent was granted to Genentech in 1989, and was successfully defended by Genentech earlier this year in opposition proceedings brought by Syntex (U.S.A.) Inc. Following extensive written briefing and oral argument, the European Patent Office (EPO) in Munich affirmed the validity of Genentech's claims to the same subject matter as covered by U.S. patent.
"The patents we have received on NGF are significant milestones in Genentech's efforts to develop therapeutics for human neurological diseases and disorders," said G. Kirk Raab, president and chief executive officer. "These patents, together with additional patent applications we have filed on NGF and other neurotrophic factors, demonstrate Genentech's scientific achievements and commitment to neuroscience research and development."
NGF is one of several naturally-occurring proteins referred to as neurotrophic factors which promote the growth or survival of nerve cells. Genentech is currently investigating NGF in clinical trials for treating peripheral neuropathy, a condition that often results from cancer chemotherapy or diabetes. Phase I clinical trials are in progress, and Phase II clinical trials are expected to begin in 1993.
Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant medical needs. The company has headquarters in South San Francisco, California and is traded on the New York and Pacific Stock exchanges under the symbol GNE.
# # #